- Home
- CGAU vs RLAY Comparison
CGAU vs RLAY Comparison
Compare CGAU & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | RLAY |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CGAU | RLAY |
|---|---|---|
| Price | $20.75 | $17.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $22.99 | ★ $27.58 |
| AVG Volume (30 Days) | 981.8K | ★ 2.3M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $36.51 | N/A |
| Revenue Next Year | N/A | $60.15 |
| P/E Ratio | $11.74 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $11.13 | $5.95 |
| 52 Week High | $24.52 | $21.27 |
Technical Indicators
Market Signals| Indicator | CGAU | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 43.82 |
| Support Level | $15.06 | $16.68 |
| Resistance Level | $21.17 | $20.09 |
| Average True Range (ATR) | 0.79 | 0.97 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 38.19 | 31.70 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.